Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
Authors
Jason J. Luke
University of Chicago Comprehensive Cancer Center, Chicago, IL
Jason J. Luke, Paolo Antonio Ascierto, Matteo S. Carlino, Alexander M. M. Eggermont, Jean-Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Jeffrey E. Gershenwald, Andrew Stewart Poklepovic, Merrick I. Ross, Richard A. Scolyer, Charles Yoon, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Vernon K. Sondak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03553836
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS145)
DOI
10.1200/JCO.2019.37.8_suppl.TPS145
Abstract #
TPS145
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.
First Author: Matteo S. Carlino
Poster
2023 ASCO Annual Meeting
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
First Author: Timothy J. Panella
Poster
2021 ASCO Annual Meeting
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
First Author: Toon Van Gorp
Poster
2019 ASCO Annual Meeting
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
First Author: Fatima Cardoso